

2. ANKÜNDIGUNG · 2ND ANNOUNCEMENT



8. International Charité-Mayo- Conference

**Updates in Gynecology:
A Global Perspective**

15.–18. April 2015
Berlin



**Live Surgeries
Intensive Workshops
CALL FOR ABSTRACTS**

www.charite-mayo.de

supported by



**GYNECOLOGIC
CANCER INTERGROUP**

An Organization of International Cooperative
Groups for Clinical Trials in Gynecologic Cancers



in vivo

- International Journal of Experimental and Clinical Pathophysiology and Drug Research
- Published bimonthly by the International Institute of Anticancer Research
- Available online with Stanford University HighWire Press

ISSN (print): 0258-851X; ISSN (online): 1791-7549

General Policy

- IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the framework of comparative physiology and pathology. The special focus of the journal is the publication of works on: (a) experimental development and the application of new diagnostic procedures; (b) pharmacological and toxicological evaluation of new drugs and drug combinations; (c) development and characterization of models for biomedical research.
- One of the principal aims of IN VIVO is to provide for the prompt publication of accepted articles, generally within 1-2 months from final acceptance.
- IN VIVO supports: (a) the aims and the research program of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH (IIAR) (Kapandriti, Attiki, Greece) and (b) the organization of the INTERNATIONAL CONFERENCES OF ANTICANCER RESEARCH.

Editorial Office

International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece. Tel and Fax: +30-22950-53389; e-mail: journals@iiar-anticancer.org

For more information about IN VIVO, IIAR and the conferences please visit the IIAR websites: www.iiar-anticancer.org and www.iv.iiarjournals.org

Selection of Recent Articles

Effect of Radiation and Repeated Sub-culturing on the Transforming Growth Factor- β 1 Signaling Pathway in FRTL-5 Cells. C.G. BURRELL, D.S. GRIDLEY, L.S. ORTLOFF, S.M. CHARLES, L.M. GREEN (*Loma Linda, CA; Winston-Salem, NC, USA*)

IL6 Plasma Concentrations in Patients with Sepsis Receiving SLED and Antibiotics: A Predictor for Survival. T.R. MCGUIRE, N.T. REARDON, K. BOGARD, T.J. PLUMB, C.J. BULTSMA, S.W. NISSEN, P.D. FULLER, K.M. OLSEN (*Omaha, NE; Ocala, FL, USA*)

Organ-specific Responses of Total Body Irradiated Doxycycline-inducible Manganese Superoxide Dismutase Tet/Tet Mice. B.H. RHIEU, A. SHINDE, M.W. EPPERLY, T. DIXON, H. WANG, R. CHAILLET, J.S. GREENBERGER (*Pittsburgh, PA, USA*)

Effect of GPIIb/IIIa Inhibition with Eptifibatid or Tirofiban on the Expression of Cellular Adhesion Molecules on Monocytes. S. SWOBODA, T. WALTER, S. LANG, H.-P. WENDEL, M.E. BEYER, E. GRIESEL, H.-M. HOFFMEISTER, J. GRUETTNER (*Heidelberg; Tuebingen; Kirchheim; Solingen, Germany*)

Tolerated Doses in Zebrafish of Cytochalasins and Jasplakinolide for Comparison with Tolerated Doses in Mice in the Evaluation of Pre-clinical Activity of Microfilament-directed Agents in Tumor Model Systems *In Vivo*. M. TRENDOWSKI, V. WONG, K. WELLINGTON, S. HATFIELD, T.P. FONDY (*Syracuse, NY, USA*)

A Novel Role of CYP2E1 in Human Megakaryocyte Development. Y. TANG, G. ZHANG, M. BAIRD, F. RACKE, W. ZHAO (*Columbus, OH; San Juan Capistrano, CA, USA*)

Efficacy and Side Effects of a Semi-individualized Chinese Herb Mixture "Tiáo Gēng Tāng" for Menopausal Syndrome in China. M. JIA, L. KLUWE, H.-C. LIU, Q.-J. TANG, L. LIU, Z.-Z. WANG, L.-X. TIAN, L. ZHAO, Y.-C. CHEN, R.E. FRIEDRICH, Z.-J. SUN, L.-W. XU (*Shanghai, PR China; Hamburg, Germany*)

Sex Hormones Differentially Modulate STAT3-dependent Antioxidant Responses during Oxidative Stress in Renal Proximal Tubule Cells. D.K. REED, I. ARANY (*Jackson, MS, USA*)

Effect of Melatonin on Human Nighttime Endotoxaemia: Randomized, Double-blinded, Cross-over Study. M. ALAMILI, K. BENDTZEN, J. LYKKESFELDT, J. ROSENBERG, I. GÖGENUR (*Køge; Copenhagen; Herlev, Denmark*)

The Success Rate in a Complicated Spatial Memory Test Is Determined by Age, Sex, Life History and Search Strategies in Cynomolgus Monkeys. H.S. DARUSMAN, O. KALLIOKOSKI, D. SAJUTHI, S.J. SCHAPIRO, A. GJEDDE, J. HAU (*Copenhagen; Aarhus, Denmark; Bogor, Indonesia; Bastrop, TX; Baltimore, MD, USA; Montréal, QC, Canada*)

No Changes in Cerebral Microcirculatory Parameters in Rat During Local Cortex Exposure to Microwaves. H. MASUDA, S. HIROTA, A. USHIYAMA, A. HIRATA, T. ARIMA, H. WATANABE, K. WAKE, S. WATANABE, M. TAKI, A. NAGAI, C. OHKUBO (*Tokyo; Saitama; Aichi, Japan*)

Improving the Bioavailability and Anticancer Effect of the PCA-1/ALKBH3 Inhibitor HUHS015 Using Sodium Salt. M. MABUCHI, T. SHIMIZU, M. UEDA, Y. SASAKAWA, S. NAKAO, Y. UEDA, A. KAWAMURA, K. TSUJIKAWA, A. TANAKA (*Kobe; Osaka; Suita; Kainan, Japan*)

CAG-repeats in Androgen Receptor Gene Relate with Plasma Androgens Levels in the Bouvier Des Flandres. H. L' EPLATTENIER, E. TESKE, F. VAN SLUIJS, J.A. MOL (*Utrecht, Netherlands*)

Bone Substitutes Enhance Osteogenic Differentiation of Mesenchymal Stem Cells in Three-dimensional Scaffolds. H. HANKEN, J. ALPERS, M. BÖBEL, M. WÖLTJE, P. HARTJEN, R.E. FRIEDRICH, O. JUNG, C. RENDENBACH, A. GRÖBE, M. HEILAND, A. AL-DAM, W. EICHHORN, R. SMEETS (*Hamburg; Aachen, Germany*)

FREE SPECIMEN COPIES OF IN VIVO ARE AVAILABLE ON REQUEST

CANCER GENOMICS & PROTEOMICS

www.cgp.iarjournals.org

Print ISSN (2004-2012): 1109-6535

Online ISSN: 1790-6245

VOL. 1 (2004) - VOL. 9 (2012) (print and online)
From VOL. 10 (2013) online – only and open access



International Online **Open Access** Journal

General Policy. CANCER GENOMICS & PROTEOMICS (CGP) welcomes submissions of original high quality articles and reviews on all aspects of the application of genomic and proteomic technologies to experimental and clinical cancer research. The journal's scientific spectrum includes: (a) molecular causes of carcinogenesis, cancer progression and metastasis; (b) structural and functional aspects of genes in the cancer cell; (c) advances in genomic and proteomic technologies applicable to cancer research; (d) anticancer drug design and drug development.

CGP will also accept abstracts and proceedings of scientific meetings for publication, following consideration and approval by the Editorial Board.

A main aim of CGP is to ensure the prompt and confidential review, and rapid publication of original works and reviews, generally within 1-3 months from submission or 1-2 months from acceptance.

CGP is published bimonthly by the **International Institute of Anticancer Research** and is available online with **Stanford University HighWire Press**. For more information please visit our website www.cgp.iarjournals.org.

Editorial Office

International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389. E-mail: journals@iiar-anticancer.org; IIAR websites: www.iiar-anticancer.org and www.iarjournals.org

A Selection of Recent Articles

The Metastasis Suppressor NME1 Regulates Expression of Genes Linked to Metastasis and Patient Outcome in Melanoma and Breast Carcinoma. J.R. MCCORKLE, M.K. LEONARD, S.D. KRANER, E.M. BLALOCK, D. MA, S.G. ZIMMER, D.M. KAETZEL (*Memphis, TN; Baltimore, MD; Lexington, KY; Iowa City, IA, USA*)

Profiling of Chromosomal Changes in Potentially Malignant and Malignant Oral Mucosal Lesions from South and South-East Asia Using Array-Comparative Genomic Hybridization. M.L.S. LUNDE, E. ROMAN, S. WARNAKULASURIYA, R. MEHROTRA, J. LARANNE, E.N. VASSTRAND, S.O. IBRAHIM (*Bergen, Norway; London, UK; Allahabad, India; Tampere, Finland*)

Expression of Claudins in Human Clear Cell Renal Cell Carcinoma. W. MEN, T.A. MARTIN, F. RUGE, N. ZHANG, P. DU, Y. YANG, W.G. JIANG (*Beijing, China; Cardiff, UK*)

TCR-MHC/Peptide Interaction: Prospects for New Anti-tumoral Agents. U.H. WEIDLE, G. GEORGES, G. TIEFENTHALER (*Penzberg, Germany*)

Modulation of Liver-Intestine Cadherin (Cadherin 17) Expression, ERK Phosphorylation and WNT Signaling in EPHB6 Receptor-expressing MDA-MB-231 Cells. L. BHUSHAN, N. TAVITIAN, D. DEY, Z. TUMUR, C. PARSA, R.P. KANDPAL (*Pomona, CA, USA*)

Phenome-Genome Association Studies of Pancreatic Cancer: New Targets for Therapy and Diagnosis. R. NARAYANAN (*Boca Raton, FL, USA*)

Usefulness of Nanofluidic Digital PCR Arrays to Quantify T790M Mutation in EGFR-mutant Lung Adenocarcinoma. K. ISOBE, Y. HATA, N. TOCHIGI, K. KABURAKI, H. KOBAYASHI, T. MAKINO, H. OTSUKA, F. ISHIDA, N. HIROTA, G. SANO, K. SUGINO, S. SAKAMOTO, Y. TAKAI, K. SHIBUYA, A. IYODA, S. HOMMA (*Tokyo, Japan*)

Quantitative Proteomics of Bronchoalveolar Lavage Fluid in Lung Adenocarcinoma. S.A. ALMATROODI, C.F. MCDONALD, A.L. COLLINS, I.A. DARBY, D.S. POUNIOTIS (*Bundoora; Heidelberg, VIC, Australia; Buraidah, Saudi Arabia*)

Metabolic profile of Triple-negative Breast Cancer in African-American Women Reveals Potential Biomarkers of Aggressive Disease. Y.M. KANAAN, B.P. SAMPEY, D. BEYENE, A.K. ESNAKULA, T.J. NAAB, L.J. RICKS-SANTI, S. DASI, A. DAY, K.W. BLACKMAN, W. FREDERICK, R.L. COPELAND, E. GABRIELSON, R.L. DEWITTY JR. (*Washington DC; Durham, NC; Cleveland, OH; Hampton, VA; Baltimore, MD, USA*)

Analysis of SHOX2 Methylation as an Aid to Cytology in Lung Cancer Diagnosis. P. ILSE, S. BIESTERFELD, N. POMJANSKI, C. WROBEL, M. SCHRAMM (*Düsseldorf, Germany*)

The Role of Apurinic/Apyrimidinic Endonuclease DNA Repair Gene in Endometriosis. C.-M. HSU, W.-S. CHANG, J.-J. HWANG, J.-Y. WANG, Y.-L. HSIAO, C.-W. TSAI, J.-C. LIU, T.-H. YING, D.-T. BAU (*Taichung; Taipei, Taiwan, ROC*)

Epigenetic Silencing of GNMT Gene in Pancreatic Adenocarcinoma. A. BOTEZATU, C. BLEOTU, A. NASTASE, G. ANTON, N. BACALBASA, D. DUDA, S.O. DIMA, I. POPESCU (*Bucharest, Romania; Charlestown, MA, USA*)

Subscription Order Form 2015

- Please enter a Subscription to ANTICANCER RESEARCH Volume 35 (2015).
Annual subscription rates (2015): Institutional, Euro 1,650.00 print or online; Personal, Euro 780.00 print or online;
Prices include rapid delivery and insurance.
2015 online subscriptions include free online access to vol. 24 (2004) - 34 (2014).
- Please send me the following previous volumes (1-34) at 50% discount on the above rates.
- Payment is enclosed. Please invoice.
Checks should be made payable to Delinasios G.J. & CO G.P. (Athens, Greece)
- Please send me information about the International Institute of Anticancer Research (IIAR).

Name and Address:

 Tel:
 Fax: e-mail:
 Signature:..... Date:.....

Please send this order to ANTICANCER RESEARCH, Subscription Office, IIAR, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece. Tel & Fax: +30-22950-53389, e-mail: subscriptions@iiar-anticancer.org

Special 2015 Offers to Authors of ANTICANCER RESEARCH

(These offers are open to all authors of articles published in Anticancer Research from 1981-2015 on a basis of priority and availability. Effective from January to December 2015).

- **Included in Pubmed, Current Contents and all abstracting and indexing services**
- **Online with Stanford University HighWire Press**
- **Open access articles**

Please complete and send this order form to:
 ANTICANCER RESEARCH, International Institute of Anticancer Research,
 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece.



Your link to the essential information on cancer research published in the last 33 years.

- 1981-2014
- 34 volumes
- over 116,000 pages
- over 16,900 original articles
- 834 reviews
- over 75,200 authors
- Conference abstracts
- Special issues
- Book reviews
- Author-Subject Indexes

Special Subscription Order Form 2015

- I am one of the authors of the article published in Anticancer Research Vol....., pp., year
- Please enter my personal subscription to Anticancer Research 2015 (Volume 35) at the special Author's rate of Euro 390.00 (print or online).
- Please send me previous Volume No(s) at Euro 195.00 (print) per volume.
- Please enter my personal combined 2015 subscription to Anticancer Research (Volume 35) and IN VIVO (Volume 29) at Euro 560.00 (print or online).
- My payment is enclosed.
- Please send me an invoice.
Prices include rapid delivery and insurance. Checks should be made payable to Delinasios G.J. & CO G.P. (Athens, Greece).

Name and address:

 Tel-Fax:
 e-mail:
 Date and signature:

Transarterial Chemoembolization with Miriplatin plus Epirubicin in Patients with Hepatocellular Carcinoma. A. TAWADA, T. CHIBA, Y. OOKA, N. KANOGAWA, T. SAITO, T. MOTOYAMA, S. OGASAWARA, E. SUZUKI, F. KANAI, M. YOSHIKAWA, O. YOKOSUKA (<i>Chiba, Japan</i>)	549
Prognostic Markers for Patient Outcome Following Vaccination with Multiple MHC Class I/II-restricted WT1 Peptide-pulsed Dendritic Cells Plus Chemotherapy for Pancreatic Cancer. K. TAKAKURA, S. KOIDO, S. KAN, K. YOSHIDA, M. MORI, Y. HIRANO, Z. ITO, H. KOBAYASHI, S. TAKAMI, Y. MATSUMOTO, M. KAJIHARA, T. MISAWA, M. OKAMOTO, H. SUGIYAMA, S. HOMMA, T. OHKUSA, H. TAJIRI (<i>Tokyo; Osaka, Japan</i>)	555
Primary Gastric Small Cell Carcinoma: A Series of Seven Cases. T. TOYOKAWA, H. TANAKA, K. MUGURUMA, T. TAMURA, K. SAKURAI, N. KUBO, M. OHIRA, K. HIRAKAWA (<i>Osaka, Japan</i>)	563
Histological Grade (HG) in Invasive Ductal Carcinomas of the Breast of Less than 1 cm: Clinical and Biological Associations During Progression from HG1 to HG3. Á. RUIBAL, P. AGUIAR, M.C. DEL RIO, J.I. ARIAS, P. MENÉNDEZ-RODRÍGUEZ, F. GUDE, M. HERRANZ (<i>Santiago de Compostela; Madrid; Ferrol; Oviedo, Spain</i>)	569
Cancer of Unknown Primary During Pregnancy: An Exceptionally Rare Coexistence. N. PAVLIDIS, F. PECCATORI, F. LOFTS, A.F. GRECO (<i>Ioannina, Greece; Milan, Italy; London, UK; Nashville, TN, USA</i>)	575
MRI Evaluation of Residual Breast Cancer After Neoadjuvant Chemotherapy: Influence of Patient, Tumor and Chemotherapy Characteristics on the Correlation with Pathological Response. C. DIGUISTO, L. OULDAMER, F. ARBION, A. VILDÉ, G. BODY (<i>Tours, France</i>).....	581
Book Reviews	587
Announcements	598

Azacitidine in the Front-line Treatment of Therapy-related Myeloid Neoplasms: A Multicenter Case Series. C. MINOIA, N. SGHERZA, G. LOSETO, G. GRECO, C. BUQUICCHIO, F. MERCHIONNE, C. TOLDO, I. GALISE, A. MELPIGNANO, G. TARANTINI, V. PAVONE, A. GUARINI (<i>Bari; Lecce; Barletta; Brindisi; Trento, Italy</i>).....	461
Phase I Study of S-1 plus Fractional Cisplatin as Adjuvant Chemotherapy for Advanced Gastric Cancer in an Outpatient Setting (KOGC-03). T. TAKAHASHI, Y. SAIKAWA, K. FUKUDA, R. NAKAMURA, N. WADA, H. KAWAKUBO, H. TAKEUCHI, H. TAKAISHI, Y. KITAGAWA (<i>Tokyo, Japan</i>)	467
Systemic Treatment Options for Epithelioid Haemangioendothelioma: The Royal Marsden Hospital Experience. N. YOUSAF, M. MARUZZO, I. JUDSON, O. AL-MUDERIS, C. FISHER, C. BENSON (<i>London, UK</i>)	473
Sunitinib-induced Thyrotoxicosis – A not so Rare Entity. M. JAZVIĆ, M. PRPIĆ, T. JUKIĆ, J. MURGIĆ, B. JAKŠIĆ, D. KUST, A. PRGOMET, A. BOLANČA, Z. KUSIĆ (<i>Zagreb, Croatia</i>)	481
Neutrophil-rich Gastric Carcinoma in the Integrated Cancer Registry of Eastern Sicily, Italy. A. IENI, G. BRANCA, A. PARISI, F. FEDELE, E. IRATO, A. VENUTI, R.A. CARUSO (<i>Messina, Italy</i>)	487
Salvage Method for Unplanned Excision of Soft Tissue Sarcoma: Longterm Results of Second-look Surgery Following Radio-hyperthermo-chemotherapy. K. HAYASHI, S. YAMADA, H. INATANI, H. OKAMOTO, A. TAKEUCHI, H. NISHIDA, N. YAMAMOTO, H. TSUCHIYA, T. OTSUKA (<i>Nagoya; Kanazawa, Japan</i>)	493
Perioperative Serum Albumin Correlates with Postoperative Pancreatic Fistula After Pancreatico-duodenectomy. Y. FUJIWARA, H. SHIBA, Y. SHIRAI, R. IWASE, K. HARUKI, K. FURUKAWA, Y. FUTAGAWA, T. MISAWA, K. YANAGA (<i>Tokyo, Japan</i>)	499
Factors Predicting Recurrence in Patients with Siewert Type II Carcinoma Treated with Curative Resection. M. FUKUCHI, E. MOCHIKI, O. SUZUKI, T. ISHIGURO, J. SOBAJIMA, H. ONOZAWA, H. IMAIZUMI, K. SHIBATA, K. SAITO, H. NAITOH, Y. KUMAGAI, K. ISHIBASHI, H. ISHIDA (<i>Saitama; Gunma, Japan</i>)	505
Assessment of Surgical Treatment and Postoperative Nutrition in Gastric Cancer Patients Older than 80 Years. T. NAKANOKO, Y. KAKEJI, K. ANDO, Y. NAKASHIMA, K. OHGAKI, Y. KIMURA, H. SAEKI, E. OKI, M. MORITA, Y. MAEHARA (<i>Fukuoka, Japan</i>)	511
Lapatinib-plus-Pegylated Liposomal Doxorubicin in Advanced HER2-positive Breast Cancer Following Trastuzumab: A Phase II Trial. M. PIRCHER, B. MLINERITSCH, M.A. FRIDRIK, C. DITTRICH, A. LANG, E. PETRU, A. WELTERMANN, J. THALER, C. HUFNAGL, S.P. GAMPENRIEDER, G. RINNERHALER, S. RESSLER, H. ULMER, R. GREIL (<i>Salzburg; Linz; Vienna; Rankweil; Graz; Grieskirchen; Innsbruck, Austria</i>)	517
MicroRNA Expressions in HPV-induced Cervical Dysplasia and Cancer. K. GOCZE, K. GOMBOS, K. KOVACS, K. JUHASZ, P. GOCZE, I. KISS (<i>Pecs, Hungary</i>).....	523
Inhibition of Placental Growth Factor in Renal Cell Carcinoma. H. BESSHO, B. WONG, D. HUANG, E.Y. SIEW, D. HUANG., J. TAN., C.K. ONG, S.Y. TAN, K. MATSUMOTO, M. IWAMURA, B.T TEH (<i>Singapore, Singapore; Kanagawa, Japan; Grand Rapids, MI, USA</i>)	531
Non-pegylated Liposomal Doxorubicin plus Ifosfamide in Metastatic Soft Tissue Sarcoma: Results from a Phase-II Trial. R. DE SANCTIS, A. BERTUZZI, U. BASSO, A. COMANDONE, S. MARCHETTI, A. MARRARI, P. COLOMBO, R.F. LUTMAN, L. GIORDANO, A. SANTORO (<i>Milan; Padova; Turin, Italy; Dublin, Ireland</i>)	543

Differential Impact of Fosaprepitant on Infusion Site Adverse Events Between Cisplatin- and Anthracycline-based Chemotherapy Regimens. T. FUJII, N. NISHIMURA, K.Y. URAYAMA, H. KANAI, H. ISHIMARU, J. KAWANO, O. TAKAHASHI, H. YAMAUCHI, T. YAMAUCHI (<i>Tokyo, Japan</i>)	379
Predicting Survival of Patients with Metastatic Epidural Spinal Cord Compression from Cancer of the Head-and-Neck. D. RADES, S.E. SCHILD, J.H. KARSTENS, S.G. HAKIM (<i>Lübeck; Hannover, Germany; Scottsdale, AZ, USA</i>)	385
Comparative Analysis of Tumor Angiogenesis and Clinical Features of 55 Cases of Pleomorphic Carcinoma and Adenocarcinoma of the Lung. Y. TSUBATA, A. SUTANI, T. OKIMOTO, I. MURAKAMI, R. USUDA, T. OKUMICHI, S.-I. KAKEGAWA, K.-I. TOGASHI, S. KOSAKA, Y. YAMASHITA, K. KISHIMOTO, T. KURAKI, T. ISOBE (<i>Izumo, Shimane; Hiroshima; Yokohama, Kanagawa; Shibukawa, Gunma; Nagaoka, Niigata, Japan</i>)	389
Multiparametric Pelvic MRI Accuracy in Diagnosing Clinically Significant Prostate Cancer in the Reevaluation of Biopsy Microfocal Tumor. P. PEPE, G. DIBENEDETTO, A. GARUFI, G. PRIOLO, M. PENNISI (<i>Catania, Italy</i>)	395
Clinical Significance of Adjuvant Surgery Following Chemotherapy for Patients with Initially Unresectable Stage IV Gastric Cancer. S. ITO, E. OKI, Y. NAKASHIMA, K. ANDO, Y. HIYOSHI, K. OHGAKI, H. SAEKI, M. MORITA, Y. SAKAGUCHI, Y. MAEHARA (<i>Fukuoka, Japan</i>)	401
Cardiac Tamponade Due to Bleeding as a Potential Lethal Complication After Surgery for Esophageal Cancer. S. ITO, M. MORITA, S. NANBARA, Y. NAKAJI, K. ANDO, Y. HIYOSHI, T. OKAMOTO, H. SAEKI, E. OKI, H. KAWANAKA, Y. TANOUE, Y. MAEHARA (<i>Fukuoka, Japan</i>)	407
Expression of Hepatocyte Growth Factor in Prostate Cancer May Indicate a Biochemical Recurrence After Radical Prostatectomy. S. NISHIDA, Y. HIROHASHI, T. TORIGOE, M. NOJIMA, R. INOUE, H. KITAMURA, T. TANAKA, H. ASANUMA, N. SATO, N. MASUMORI (<i>Sapporo; Tokyo, Japan</i>)	413
Benefit of Neoadjuvant Chemotherapy for Siewert Type II Esophagogastric Junction Adenocarcinoma. K. HOSODA, K. YAMASHITA, N. KATADA, H. MORIYA, H. MIENO, S. SAKURAMOTO, S. KIKUCHI, M. WATANABE (<i>Sagamihara, Kanagawa; Hidaka, Saitama, Japan</i>)	419
Surgical Treatment of Metastatic Femoral Fractures: Achieving an Improved Quality of Life for Cancer Patients. M. MORISHIGE, K. MURAMATSU, Y. TOMINAGA, T. HASHIMOTO, T. TAGUCHI (<i>Ube, Yamaguchi, Japan</i>)	427
Survival in Patients with Clear Cell Renal Cell Carcinoma Is Predicted by HIF-1 α Expression. D. MINARDI, G. LUCARINI, M. SANTONI, R. MAZZUCHELLI, L. BURATTINI, A. CONTI, E. PRINCIPI, M. BIANCONI, M. SCARTOZZI, G. MILANESE, R. DI PRIMIO, R. MONTIRONI, S. CASCINU, G. MUZZONIGRO (<i>Ancona, Italy</i>)	433
Deregulation of Glyceraldehyde-3-Phosphate Dehydrogenase Expression During Tumor Progression of Human Cutaneous Melanoma. D. RAMOS, A. PELLÍN-CARCELÉN, J. AGUSTÍ, A. MURGUI, E. JORDÁ, A. PELLÍN, C. MONTEAGUDO (<i>Valencia, Spain</i>)	439
Impact of Lower Mediastinal Lymphadenectomy for the Treatment of Esophagogastric Junction Carcinoma. K. HOSODA, K. YAMASHITA, N. KATADA, H. MORIYA, H. MIENO, S. SAKURAMOTO, S. KIKUCHI, M. WATANABE (<i>Kanagawa, Japan</i>)	445
Impact of Clinical Pharmacy Services in a Hematology/Oncology Inpatient Setting. A. DELPEUCH, D. LEVEQUE, B. GOURIEUX, R. HERBRECHT (<i>Strasbourg, France</i>)	457

Clinical Studies

Urological Procedures in Patients with Peritoneal Carcinomatosis of Colorectal Cancer Treated with HIPEC: Morbidity and Survival Analysis. H.J. BRAAM, T.R. VAN OUDHEUSDEN, I.H.J.T. DE HINGH, S.W. NIENHUIJS, D. BOERMA, M.J. WIEZER, B. VAN RAMSHORST (*Nieuwegein; Eindhoven, Netherlands*) 295

Prognostic Significance of Microscopic Tumor Burden in Sentinel Lymph Node in Patients with Cutaneous Melanoma. C. KIM, S. ECONOMOU, T.T. AMATRUDA, J.C. MARTIN, A.Z. DUDEK (*Minneapolis; Edina; Fridley, MN; Chicago, IL, USA*) 301

Presence of CD3-Positive T-Cells in Oral Premalignant Leukoplakia Indicates Prevention of Cancer Transformation. J. ÖHMAN, R. MOWJOOD, L. LARSSON, A. KOVACS, B. MAGNUSSON, G. KJELLER, M. JONTELL, B. HASSEUS (*Gothenburg, Sweden*)..... 311

CT-Guided Brachytherapy as Salvage Therapy for Intrahepatic Recurrence of HCC After Surgical Resection. D. SCHNAPAUFF, F. COLLETTINI, K. HARTWIG, G. WIENERS, S. CHOPRA, B. HAMM, B. GEBAUER (*Berlin, Germany*)..... 319

Single Hepatocellular Carcinoma Smaller than 2 cm: Are Ethanol Injection and Radiofrequency Ablation Equally Effective? M. POMPILI, N. DE MATTHAEIS, A. SAVIANO, I. DE SIO, G. FRANCICA, F. BRUNELLO, A. CANTAMESSA, A. GIORGIO, U. SCOGNAMIGLIO, F. FORNARI, F. GIANGREGORIO, F. PISCAGLIA, S. GUALANDI, E. CATURELLI, P. ROSELLI, L. RICCARDI, G.L. RAPACCINI (*Rome; Naples; Castel Volturno; Turin; Piacenza; Bologna; Viterbo, Italy*) 325

Radiosurgery with 20 Gy Provides Better Local Control of 1-3 Brain Metastases from Breast Cancer than with Lower Doses. D. RADES, S. HUTTENLOCHER, V. RUDAT, D. HORNUNG, O. BLANCK, P.C. PHUONG, M.T. KHOA, S.E. SCHILD, D. FISCHER (*Lübeck; Hamburg; Güstrow, Germany; Al Khobar, Saudi Arabia; Hanoi, Vietnam; Scottsdale, AZ, USA*)..... 333

Pre-treatment Neutrophil to Lymphocyte Ratio Is a Predictor of Prognosis in Endometrial Cancer. T. HARUMA, K. NAKAMURA, T. NISHIDA, C. OGAWA, T. KUSUMOTO, N. SEKI, Y. HIRAMATSU (*Okayama, Japan*) 337

Immunohistochemical, Cytogenetic, and Molecular Cytogenetic Characterization of Both Components of a Dedifferentiated Liposarcoma: Implications for Histogenesis. J. NISHIO, H. IWASAKI, K. NABESHIMA, M. NAITO (*Fukuoka, Japan*) 345

Paucity of Tumor-infiltrating Lymphocytes Is an Unfavorable Prognosticator and Predicts Lymph Node Metastases in Cutaneous Melanoma Patients. P. DONIZY, M. KACZOROWSKI, A. HALON, M. LESKIEWICZ, C. KOZYRA, R. MATKOWSKI (*Wroclaw, Poland*) 351

Usefulness of Duloxetine for Paclitaxel-Induced Peripheral Neuropathy Treatment in Gynecological Cancer Patients. A. OTAKE, K. YOSHINO, Y. UEDA, K. SAWADA, S. MABUCHI, T. KIMURA, E. KOBAYASHI, A. ISOBE, T. EGAWA-TAKATA, S. MATSUZAKI, M. FUJITA, T. KIMURA (*Osaka, Japan*)..... 359

Impact of Adjuvant Pelvic Radiotherapy in Stage I Uterine Sarcoma. W.J. MAGNUSON, D.G. PETEREIT, B.M. ANDERSON, H.M. GEYE, K.A. BRADLEY (*Madison, WI; Rapid City, SD, USA*) 365

Reduced Dose of Salvage-line Regorafenib Monotherapy for Metastatic Colorectal Cancer in Japan. G. HIRANO, A. MAKIYAMA, C. MAKIYAMA, T. ESAKI, H. ODA, K. UCHINO, M. KOMODA, R. TANAKA, Y. MATSUSHITA, K. MITSUGI, Y. SHIBATA, H. KUMAGAI, S. ARITA, H. ARIYAMA, H. KUSABA, K. AKASHI, E. BABA (*Kitakyushu; Fukuoka; Miyazaki, Japan*)..... 371

<i>In Vitro</i> Anticancer Activity of PI3K Alpha Selective Inhibitor BYL719 in Head and Neck Cancer. B. KEAM, S. KIM, Y.-O. AHN, T.M. KIM, S.-H. LEE, D.-W. KIM, D.S. HEO (<i>Seoul, Republic of Korea</i>).....	175
KML001 Enhances Anticancer Activity of Gemcitabine Against Pancreatic Cancer Cells. M.H. YANG, K.T. LEE, S. YANG, J.K. LEE, K.H. LEE, J.C. RHEE (<i>Seoul, Republic of Korea</i>)	183
Cytotoxic Effect of <i>S</i> -Petasin and Iso- <i>S</i> -Petasin on the Proliferation of Human Prostate Cancer Cells. Z.-H. WANG, H.-W. HSU, J.-C. CHOU, C.-H. YU ,D.-T. BAU, G.-J. WANG, C.-Y. HUANG, P.S. WANG, S.-W. WANG (<i>Taichung; Taipei, Taiwan, ROC</i>).....	191
Dendrofalconerol A Suppresses Migrating Cancer Cells <i>via</i> EMT and Integrin Proteins. P. PENGPAENG, B. SRITULARAK, P. CHANVORACHOTE (<i>Bangkok, Thailand</i>).....	201
Comparative Effects Between Fucoxanthinol and its Precursor Fucoxanthin on Viability and Apoptosis of Breast Cancer Cell Lines MCF-7 and MDA-MB-231. A. RWIGEMERA, J. MAMELONA, L.J. MARTIN (<i>Moncton, NB, Canada</i>).....	207
Active Estrogen Synthesis and its Function in Prostate Cancer-derived Stromal Cells. K. MACHIOKA, A. MIZOKAMI, Y. YAMAGUCHI, K. IZUMI, S. HAYASHI, M. NAMIKI (<i>Ishikawa; Saitama; Sendai, Japan</i>)	221
Discovery of PAT-1102, a Novel, Potent and Orally Active Histone Deacetylase Inhibitor with Antitumor Activity in Cancer Mouse Models. J. HIRIYAN, P. SHIVARUDRAIAH, G. GAVARA, P. ANNAMALAI, S. NATESAN, G. SAMBASIVAM, S.K. SUKUMARAN (<i>Bangalore; Chennai; Hosur, India</i>).....	229
Cancer Stem Cell Marker in Circulating Tumor Cells: Expression of CD44 Variant Exon 9 Is Strongly Correlated to Treatment Refractoriness, Recurrence and Prognosis of Human Colorectal Cancer. S. KATOH, T. GOI, T. NARUSE, Y. UEDA, H. KUREBAYASHI, T. NAKAZAWA, Y. KIMURA, Y. HIRONO, A. YAMAGUCHI (<i>Fukui, Japan</i>)	239
Epidermal Growth Factor-induced Cell Death and Radiosensitization in Epidermal Growth Factor Receptor-overexpressing Cancer Cell Lines. K. KIM, H.-G. WU, S.-R. JEON (<i>Seoul, Republic of Korea</i>)	245
Determination of Gene Expression and Serum Levels of MnSOD and GPX1 in Colorectal Cancer. I. NALKIRAN, S. TURAN, S. ARIKAN, Ö. TIMIRCI KAHRAMAN, L. ACAR, I. YAYLIM, A. ERGEN (<i>Rize; Istanbul, Turkey</i>)	255
<i>FOXD1</i> Expression Is Associated with Poor Prognosis in Non-small Cell Lung Cancer. S. NAKAYAMA, K. SOEJIMA, H. YASUDA, S. YODA, R. SATOMI, S. IKEMURA, H. TERAJ, T. SATO, N. YAMAGUCHI, J. HAMAMOTO, D. ARAI, K. ISHIOKA, K. OHGINO, K. NAOKI, T. BETSUYAKU (<i>Tokyo, Japan; New York, NY, USA</i>)	261
<i>Akt1</i> rs2498801 Is Related to Survival in Head and Neck Squamous Cell Cancer Treated with Radiotherapy. F. PASQUALETTI, G. BOCCI, V. MEY, V. MENGHINI, S. MONTRONE, P. COCUZZA, P. FERRAZZA, V. SECCIA, D. DELISHAJ, C. ORLANDINI, M.G. FABRINI, R. DANESI (<i>Pisa, Italy</i>).....	269
Resveratrol at Anti-angiogenesis/Anticancer Concentrations Suppresses Protein Kinase G Signaling and Decreases IAPs Expression in HUVECs. J.C. WONG, R.R. FISCUS (<i>Las Vegas; Henderson, NV, USA</i>)	273
Anticancer Effects of Brominated Indole Alkaloid Eudistomin H from Marine Ascidian <i>Eudistoma viride</i> Against Cervical Cancer Cells (HeLa). R.P. RAJESH, M. ANNAPPAN (<i>Bangalore; Tuticorin, India</i>).....	283

Targeting Chemokine Receptor CXCR7 Inhibits Glioma Cell Proliferation and Mobility. Y. LIU, E. CARSON-WALTER, K.A. WALTER (<i>Rochester, NY, USA</i>)	65
Enlargement and Multinucleation of U937 Leukemia and MCF7 Breast Carcinoma Cells by Antineoplastic Agents to Enhance Sensitivity to Low Frequency Ultrasound and to DNA-directed Anticancer Agents. M. TRENDOWSKI, V. WONG, G. YU, T.P. FONDY (<i>Syracuse, NY, USA</i>)	77
Dual Targeting NG2 and GD3A Using Mab-Zap Immunotoxin Results in Reduced Glioma Cell Viability <i>In Vitro</i> . S.C. HIGGINS, H.L. FILLMORE, K. ASHKAN, A.M. BUTT, G.J. PILKINGTON (<i>Portsmouth; London, UK</i>)	85
Differential Contribution of ROS to Resveratrol-induced Cell Death and Loss of Self-renewal Capacity of Ovarian Cancer Stem Cells. M. SEINO, M. OKADA, K. SHIBUYA, S. SEINO, S. SUZUKI, H. TAKEDA, T. OHTA, H. KURACHI, C. KITANAKA (<i>Yamagata; Tokyo; Osaka, Japan</i>)	97
Oil Palm Phenolics (OPP) Inhibit Pancreatic Cancer Cell Proliferation <i>via</i> Suppression of NF- κ B Pathway. X. JI, A. USMAN, N.H. RAZALLI, R. SAMBANTHAMURTHI, S.V. GUPTA (<i>Detroit, MI, USA; Selangor, Malaysia</i>)	107
Pattern of IGF-1 Variants' Expression in Human Cancer Cell Lines Using a Novel q-RT-PCR Approach. P.F. CHRISTOPOULOS, A. PHILIPPOU, M. KOUTSILIERIS (<i>Athens, Greece</i>)	107
Is Relative Quantification Dispensable for the Measurement of MicroRNAs as Serum Biomarkers in Germ Cell Tumors? M. SPIEKERMANN, K.-P. DIECKMANN, T. BALKS, J. BULLERDIEK, G. BELGE (<i>Bremen; Hamburg; Rostock, Germany</i>)	117
Diminished Expression of <i>MiR-15a</i> Is an Independent Prognostic Marker for Breast Cancer Cases. Y. SHINDEN, S. AKIYOSHI, H. UEO, S. NAMBARA, T. SAITO, H. KOMATSU, M. UEDA, H. HIRATA, S. SAKIMURA, R. UCHI, Y. TAKANO, T. IGUCHI, H. EGUCHI, K. SUGIMACHI, Y. KIJIMA, H. UEO, S. NATSUGOE, K. MIMORI (<i>Beppu; Fukuoka; Kagoshima; Haya, Japan</i>)	123
Combination Immunotherapy with 4-1BB Activation and PD-1 Blockade Enhances Antitumor Efficacy in a Mouse Model of Subcutaneous Tumor. Y. SHINDO, K. YOSHIMURA, A. KURAMASU, Y. WATANABE, HIDEAKI ITO, T. KONDO, A. OGA, HIROSHI ITO, S. YOSHINO, S. HAZAMA, K. TAMADA, H. YAGITA, M. OKA (<i>Ube; Tokyo, Japan</i>)	129
Vascular Endothelial Growth Factor, Basic Fibroblast Growth Factor and Epithelial Growth Factor Receptor in Peripheral Nerve Sheath Tumors of Neurofibromatosis Type 1. R.E. FRIEDRICH, C. BEER, M. GLATZEL, C. HAGEL (<i>Hamburg, Germany</i>)	137
Verification of a Canine PSMA (FolH1) Antibody. S. WAGNER, D. MAIBAUM, A. PICH, I. NOLTE, H.M. ESCOBAR (<i>Hannover; Rostock, Germany</i>)	145
CD47 Activation-induced UHRF1 Over-expression is Associated with Silencing of Tumor Suppressor Gene <i>p16^{INK4A}</i> in Glioblastoma Cells. A. BOUKHARI, M. ALHOSIN, C. BRONNER, K. SAGINI, C. TRUCHOT, E. SICK, V.B. SCHINI-KERTH, P. ANDRÉ, Y. MÉLY, M. MOUSLI, J.-P. GIES (<i>Illkirch, France</i>)	149
Human Adipose Tissue-derived Mesenchymal Stem Cells Inhibit Melanoma Growth <i>In Vitro</i> and <i>In Vivo</i> . J.-O. AHN, Y.-R. COH, H.-W. LEE, I.-S. SHIN, S.-K. KANG, H.-Y. YOUN (<i>Seoul, Republic of Korea</i>) ...	159
Influence of p53 Status on the Effects of Boron Neutron Capture Therapy in Glioblastoma. K. SEKI, Y. KINASHI, S. TAKAHASHI (<i>Osaka, Japan</i>)	169